Aurinia Pharmaceuticals (AUPH) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Aurinia Pharmaceuticals (AUPH) is Neutral.

The composite score behind that read is +0.13, weighing +0.13 of bullish evidence against -0.31 bearish.

Aurinia Pharmaceuticals last closed at $16.65, +2.65% on the session.

Against the IVW growth benchmark the position is +1.85% over the forecast window.

The read is built from 15 underlying insights — 11 bullish and 4 bearish.

Agreement across those insights is 73%.

Aurinia Pharmaceuticals has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Aurinia Pharmaceuticals in the 93rd percentile on valuation and the 93rd percentile on return on equity, where 100 is best.

Aurinia Pharmaceuticals is classified under Health Care / Biotechnology, with a market capitalisation of $2.16B.

StockMap tracks Aurinia Pharmaceuticals as the 82nd largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Aurinia Pharmaceuticals ranks 32nd of 381 in the group, against a group median of -0.08.